Edition:
United Kingdom

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

43.80USD
14 Dec 2018
Change (% chg)

$-0.77 (-1.73%)
Prev Close
$44.57
Open
$44.06
Day's High
$44.12
Day's Low
$43.43
Volume
10,271,221
Avg. Vol
6,526,222
52-wk High
$46.46
52-wk Low
$33.20

Chart for

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  PFE.N Industry Sector
P/E (TTM): 26.26 31.13 34.39
EPS (TTM): 1.37 -- --
ROI: 6.00 15.55 14.96
ROE: 13.80 16.92 16.52

Pfizer's cut-price version of Avastin wins EU panel greenlight

A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.

14 Dec 2018

Pfizer's cut-price version of Avastin wins EU panel greenlight

Dec 14 A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.

14 Dec 2018

UPDATE 3-Bayer to sell businesses, cut jobs after Monsanto deal

* Around 12,000 jobs to go (Adds asset values, potential buyers of animal health unit)

29 Nov 2018

Merck raised prices five drugs including Keytruda in November

NEW YORK Merck & Co Inc said on Wednesday it raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.

28 Nov 2018

Merck raised prices five drugs including Keytruda in November

NEW YORK, Nov 28 Merck & Co Inc said on Wednesday it raised U.S. prices on five of its drugs earlier in November by between 1.5 percent and 6 percent, including its top-selling cancer treatment Keytruda.

28 Nov 2018

Swiss stocks - Factors to watch on Nov. 28

ZURICH/BERLIN, Nov 28 The Swiss blue-chip SMI was seen opening 0.3 percent higher at 8,925 points on Wednesday, according to premarket indications by bank Julius Baer.

28 Nov 2018

Deals of the day-Mergers and acquisitions

Nov 27 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

27 Nov 2018

Roche buys U.S. biotech Jecure in race for liver disease drugs

ZURICH Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

27 Nov 2018

Roche buys U.S. biotech Jecure in race for liver disease drugs

ZURICH, Nov 27 Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.

27 Nov 2018

UPDATE 2-Bayer looks at options for consumer brands, animal health -sources

* Bayer seeks to cut debt in wake of Monsanto takeover (Adds detail, context)

26 Nov 2018

Earnings vs. Estimates